Another Forest Investor Says $25B Actavis Offer Is Weak
Another investor in Carl Icahn-backed Forest Laboratories Inc. recently sued the pharmaceutical company in New York court to block generic-drug maker Actavis PLC's proposed $25 billion acquisition of the company, calling...To view the full article, register now.
Already a subscriber? Click here to view full article